1. Home
  2. GILD
  3. GILD News

Latest Gilead Sciences Inc. (GILD) News on September 16, 2025

GILD

MT Newswires

12 hours ago

JPMorgan Adjusts Price Target on Gilead Sciences to $145 From $135, Maintains Overweight Rating

3 Reasons GILD is Risky and 1 Stock to Buy Instead
GILD

StockStory

18 hours ago

3 Reasons GILD is Risky and 1 Stock to Buy Instead

Alger Russell Innovation Index Updates for Third Quarter 2025
GILD

PR Newswire

a day ago

Alger Russell Innovation Index Updates for Third Quarter 2025

Why California’s biopharma boom is critical for logistics
GILD

FreightWaves

a day ago

Why California’s biopharma boom is critical for logistics

GILD

Investing.com

3 days ago

Biotech stocks: Who wins and who loses if RFK, Jr. goes

Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock
GILD

Benzinga

4 days ago

Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock

GILD

MT Newswires

4 days ago

Rothschild & Co Redburn Adjusts Gilead Sciences Price Target to $143 From $136, Maintains Buy Rating

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
GILD

Zacks

5 days ago

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Biotechs Could Benefit If RFK Jr. Leaves HHS
GILD

GuruFocus.com

5 days ago

Biotechs Could Benefit If RFK Jr. Leaves HHS

Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite
GILD

Simply Wall St.

5 days ago

Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite

The ELC Awards $2 Million in Scholarships to More Than 100 Emerging Business Leaders in 2025 Cohort
GILD

PR Newswire

5 days ago

The ELC Awards $2 Million in Scholarships to More Than 100 Emerging Business Leaders in 2025 Cohort

GILD

MT Newswires

6 days ago

Veeva Systems Expands Partnership With Gilead Sciences

Gilead Sciences Commits to Veeva Vault CRM
GILD

PR Newswire

6 days ago

Gilead Sciences Commits to Veeva Vault CRM

Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating
GILD

Insider Monkey

7 days ago

Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating

GILD

MT Newswires

7 days ago

Xilio Therapeutics Starts Phase 2 Trial for Potential Anti-Tumor Monotherapy, Achieves $17.5 Million Development Milestone Under License Deal With Gilead

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
GILD

Business Wire

7 days ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025
GILD

Simply Wall St.

7 days ago

What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
GILD

GlobeNewswire

7 days ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies
GILD

GlobeNewswire

7 days ago

Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies

WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.
GILD

PR Newswire

8 days ago

WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.

GILD

MT Newswires

8 days ago

Ideaya Reports 'Positive' Initial Data on Trodelvy Combination Trial in Urothelial Cancer

GILD

Argus Research

8 days ago

Weekly Stock List

Leerink Partners Maintains Buy on Gilead Sciences (GILD)
GILD

Insider Monkey

9 days ago

Leerink Partners Maintains Buy on Gilead Sciences (GILD)

Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy
GILD

Insider Monkey

11 days ago

Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy

Gilead Sciences advances HIV prevention with new US partnership
GILD

Pharmaceutical Technology

12 days ago

Gilead Sciences advances HIV prevention with new US partnership

The US will buy 2 million doses of an HIV prevention drug for low-income countries
GILD

Associated Press Finance

12 days ago

The US will buy 2 million doses of an HIV prevention drug for low-income countries

GILD

MT Newswires

12 days ago

Gilead Sciences Collaborates With PEPFAR to Make HIV Drug Lenacapavir Accessible Across Countries

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
GILD

Business Wire

12 days ago

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
GILD

Insider Monkey

12 days ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer
GILD

GlobeNewswire

12 days ago

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva
GILD

GlobeNewswire

12 days ago

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
GILD

Business Wire Videos

12 days ago

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
GILD

Business Wire Videos

12 days ago

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
GILD

PR Newswire

13 days ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

Is Gilead Sciences Stock Underperforming the Nasdaq?
GILD

Barchart

13 days ago

Is Gilead Sciences Stock Underperforming the Nasdaq?

GILD

MT Newswires

13 days ago

Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ

Gilead starts building manufacturing hub under $32 billion planned US investments
GILD

Reuters

13 days ago

Gilead starts building manufacturing hub under $32 billion planned US investments

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
GILD

Business Wire

13 days ago

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

1 Healthcare Stock to Consider Right Now and 2 We Question
GILD

StockStory

14 days ago

1 Healthcare Stock to Consider Right Now and 2 We Question

What Do Analysts Think About Gilead Sciences (GILD)?
GILD

Insider Monkey

14 days ago

What Do Analysts Think About Gilead Sciences (GILD)?

Gilead Sciences, Inc. (GILD) Wins FDA Approval for World’s First Twice-Yearly HIV Preventive Therapy
GILD

Insider Monkey

15 days ago

Gilead Sciences, Inc. (GILD) Wins FDA Approval for World’s First Twice-Yearly HIV Preventive Therapy

Wyoming State Buys European Bank Stocks, Adjusts Healthcare Holdings
GILD

Barrons.com

16 days ago

Wyoming State Buys European Bank Stocks, Adjusts Healthcare Holdings

Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission
GILD

Insider Monkey

17 days ago

Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission

GILD

MT Newswires

18 days ago

Gilead Sciences Insider Sold Shares Worth $1,136,300, According to a Recent SEC Filing

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
GILD

Zacks

19 days ago

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

The Bull Case For Gilead Sciences (GILD) Could Change Following European Approval of Twice-Yearly HIV Prevention Injection
GILD

Simply Wall St.

20 days ago

The Bull Case For Gilead Sciences (GILD) Could Change Following European Approval of Twice-Yearly HIV Prevention Injection

Analyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why
GILD

Insider Monkey

21 days ago

Analyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why

GILD

Argus Research

21 days ago

The Argus High-Yield Model Portfolio

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
GILD

Zacks

21 days ago

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win
GILD

Investor's Business Daily

21 days ago

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win

Gilead’s Yeytuo approved in EU, boosting its blockbuster potential
GILD

Pharmaceutical Technology

21 days ago

Gilead’s Yeytuo approved in EU, boosting its blockbuster potential

GILD

Investing.com

22 days ago

Gilead wins European approval for HIV prevention injection

GILD

MT Newswires

22 days ago

Gilead Sciences Says HIV Prevention Shot Yeytuo Approved in EU

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
GILD

Business Wire

22 days ago

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
GILD

Zacks

25 days ago

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

This Overlooked Biotech Stock Is a Buy for Its Hidden Strengths
GILD

Barchart

25 days ago

This Overlooked Biotech Stock Is a Buy for Its Hidden Strengths

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m
GILD

Pharmaceutical Technology

25 days ago

Gilead’s Kite scoops in vivo CAR-T specialist Interius for $350m

Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
GILD

Investor's Business Daily

a month ago

Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug

GILD

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Late Afternoon

GILD

MT Newswires

a month ago

Sector Update: Health Care

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.
GILD

Barrons.com

a month ago

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

Why Gilead Sciences (GILD) Shares Are Sliding Today
GILD

StockStory

a month ago

Why Gilead Sciences (GILD) Shares Are Sliding Today

Coty, Gilead Sciences, Rent the Runway: Trending tickers
GILD

Yahoo Finance Video

a month ago

Coty, Gilead Sciences, Rent the Runway: Trending tickers

Stocks Pressured by Weak Walmart Earnings and Higher Bond Yields
GILD

Barchart

a month ago

Stocks Pressured by Weak Walmart Earnings and Higher Bond Yields

Stock Market Today: Dow Jones Index Falls After Surprise Jobless Claims; Walmart Tumbles On Earnings Miss (Live Coverage)
GILD

Investor's Business Daily

a month ago

Stock Market Today: Dow Jones Index Falls After Surprise Jobless Claims; Walmart Tumbles On Earnings Miss (Live Coverage)

GILD

MT Newswires

a month ago

Gilead Sciences Unit to Acquire Interius BioTherapeutics for $350 Million

GILD

Investing.com

a month ago

Gilead stock falls after CVS holds off adding HIV prevention shot to plans

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
GILD

Business Wire

a month ago

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

Dow Jones Futures Fall Amid Walmart Earnings, Meta News After Palantir-Led Rally Off Lows
GILD

Investor's Business Daily

a month ago

Dow Jones Futures Fall Amid Walmart Earnings, Meta News After Palantir-Led Rally Off Lows

GILD

MT Newswires

a month ago

Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet

Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists
GILD

Reuters

a month ago

Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

Gilead Sciences to Present at Upcoming Investor Conferences
GILD

Business Wire

a month ago

Gilead Sciences to Present at Upcoming Investor Conferences

BTS and clients recognized with 59 Brandon Hall Group Excellence Awards in 2025
GILD

Business Wire

a month ago

BTS and clients recognized with 59 Brandon Hall Group Excellence Awards in 2025

GILD

MT Newswires

a month ago

Bernstein Adjusts Price Target on Gilead Sciences to $135 From $120, Maintains Outperform Rating

GILD

MT Newswires

a month ago

Walgreens Specialty Pharmacy Expands Limited Distribution Network

GILD

MT Newswires

a month ago

Daiwa Upgrades Gilead Sciences to Outperform From Neutral, Adjusts Price Target to $128 From $104

GILD

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $3,318,927, According to a Recent SEC Filing

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
GILD

Zacks

a month ago

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

GILD

MT Newswires

a month ago

Argus Adjusts Price Target on Gilead Sciences to $130 From $120

GILD

Argus Research

a month ago

Analyst Report: Gilead Sciences, Inc.

GILD

Argus Research

a month ago

Market Digest: CHH, GILD, HOLX, WTRG, FTV, FOXA, OTIS, DUOL, RDDT

GILD

MT Newswires

a month ago

Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating

The Saturday Spread: These 3 Stocks Statistically May Be Cooking Up Something Special (GILD, WMB, XPEV)
GILD

Barchart

a month ago

The Saturday Spread: These 3 Stocks Statistically May Be Cooking Up Something Special (GILD, WMB, XPEV)

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
GILD

Zacks

a month ago

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve
GILD

Simply Wall St.

a month ago

We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve

Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
GILD

StockStory

a month ago

Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions

Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
GILD

StockStory

a month ago

Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks

GILD

Argus Research

a month ago

Technical Assessment: Bullish in the Intermediate-Term

GILD

MT Newswires

a month ago

Market Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog

GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus
GILD

StockStory

a month ago

GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus

Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir
GILD

Insider Monkey

a month ago

Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir

GILD

MT Newswires

a month ago

Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $136 From $132

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
GILD

Zacks

a month ago

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

GILD

MT Newswires

a month ago

Deutsche Bank Adjusts Gilead Sciences Price Target to $135 From $120, Maintains Buy Rating

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
GILD

GlobeNewswire

a month ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Company News for Aug 11, 2025
GILD

Zacks

a month ago

Company News for Aug 11, 2025

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.
GILD

Barrons.com

a month ago

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish
GILD

Insider Monkey

a month ago

Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish

Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations
GILD

Simply Wall St.

a month ago

Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations

Nasdaq posts record closing high with tech gains, rate cut optimism
GILD

Reuters Videos

a month ago

Nasdaq posts record closing high with tech gains, rate cut optimism

Share on Social Networks: